Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
cell therapy
3
×
life sciences
national
national blog main
novartis
3
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
clinical trials
detroit blog main
detroit top stories
diagnostics
gene therapy
immunotherapy
indiana blog main
indiana top stories
medicare
merck
national top stories
new york blog main
new york top stories
nivolumab
pembrolizumab keytruda
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
What
new
3
×
bio
drug
roundup
advantages
approval
bar
biogen’s
biopharmaceutical
brings
chemistry
cmc
companies
consistent
controls
convo
earlier
ensure
expect
failures
fda
gamble
gene
lack
littered
manufacturing
market
medco’s
mover
nash
needed
news
official
patients
payers
physicians
plan
playbook
price
pricing
Language
unset
Current search:
novartis
×
new
×
" cell therapy "
×
@xconomy.com
3 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
